Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Morrow Bank's Swedish subsidiary has received a banking license

Vinge has advised Morrow Bank ASA in connection with its subsidiary Morgon Finans AB (under name change to Morrow Bank AB) being granted a Swedish license to conduct banking operations by the Swedish Financial Supervisory Authority.
April 02, 2025

Vinge has advised VARO Energy Marketing AG in its acquisition of Corral Petroleum Holdings AB, the parent company of the Preem group

 Preem operates around 500 filling stations in Sweden, as well as refineries in Lysekil and Gothenburg which in total represent over 40% of Sweden’s energy needs for transportation and 80% of its refining capacity. Preem and Varo will jointly become Europe’s second largest renewable fuel producer and account for almost 10% of all road and marine fuels sold in Europe.
March 31, 2025

Vinge advises Geveko on inaugural EUR 170 million senior secured bond issuance and super senior RCF

 Vinge has advised Geveko Holding AB (publ) on its inaugural issuance of senior secured floating rate bonds in an amount of EUR 170 million (under a total framework of EUR 325 million), as well as on the entry into a super senior revolving credit facility with a Nordic bank.
March 31, 2025